13 April 2011, Singapore. Specialized biologics will soon be made right here in Singapore to service the booming biomedical science industry regionally.
Newly launched biotech company Singapore Advanced Biologics (SABio) will focus on the design, synthesis and validation of specialised biologics or medicinal products, with an initial focus on siRNA, DNA and antibodies.
‘SABio’s high quality products will enjoy the valued status of the ‘Made in Singapore’ brand and thus support the vision of Singapore as a research and biomedicine hub,’ said Rene Jaeggi, SABio’s managing director.
SABio was founded by two entrepreneurial researchers at the Duke-NUS Graduate Medical School, Mariano Garcia-Blanco and Subhash Vasudevan.
It also recently closed its Series A financing with an investment from BV Healthcare II, a life science fund managed by BioVeda Capital.